Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
暂无分享,去创建一个
A. Stuckey | L. Molinero | S. Pignata | S. Hietanen | J. Sehouli | C. Aghajanian | M. Bookman | R. Penson | R. Mądry | A. Lortholary | S. Nishio | Yvonne G Lin | L. Copeland | Xiaohua Wu | Sheetal Patel | V. Khor | C. Anderson | Ç. Taşkıran | L. Willmott | J. Thomes-Pepin | K. Moore | A. Miller | C. McCourt | T. Myers | Yvette He